This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Endo Pharmaceuticals Holdings Inc. (
Q4 2011 Earnings Call
February 24, 2012 8:30 am ET
David Holveck – President, Chief Executive Officer
Alan Levin – Executive Vice President, Chief Financial Officer
Julie McHugh – Chief Operating Officer
Dr. Ivan Gergel – Chief Scientific Officer
Blaine Davis – Vice President, Corporate Affairs
Gregg Gilbert – Bank of America Merrill Lynch
John Boris – Citigroup
Shibani Malhotra – RBC Capital Markets
Corey Davis – Jefferies
David Ansellem – Piper Jaffray
Ken Cacciatore – Cowen & Co.
Chris Schott – JP Morgan
Annabel Samimy – Stifel Nicolaus
Jim Dawson – Buckingham Research
Michael Tong – Wells Fargo
Gary Nachman – Susquehanna Financial Group
Good day ladies and gentlemen and welcome to the Fourth Quarter 2011 Endo Pharmaceuticals Holdings Inc. Earnings conference call. My name is Lacey and I’ll be your coordinator for today. At this time, all participants are in listen-only mode. We will facilitate a question and answer session towards the end of the presentation. If at any time during the call you require assistance, please press star followed by zero and a coordinator will be happy to assist you. As a reminder, this conference is being recorded for replay purposes.
I would now like to turn the presentation over to your host for today’s call, Mr. Blaine Davis, Vice President of Corporate Affairs. Please proceed.
Great, thanks Lacey. Good morning everybody and thank you for joining us. With me on this morning’s call are Dave Holveck, President and CEO of Endo; Julie McHugh, Chief Operating Officer; Dr. Ivan Gergel, Chief Scientific Officer, and Alan Levin, Chief Financial Officer. After our prepared remarks, we’ll open the call to your questions.